Skip to Main Content
American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
American Flag

Agenus Inc.

AGEN Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Compensation
Government
Ownership
News
Income
Balance Sheet
Cash Flow
Revenue Breakdown

Recent trades of AGEN by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
AGEN Stock Insider Trading Activity Follow @QuiverQuant for major insider updates

---

Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
AGEN Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
AGEN Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported

Recently reported changes in AGEN holdings by institutional investors

Quarterly net insider trading by AGEN's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions

Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.

  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More about Alpha
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More about Annual Standard Deviation
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More about Annual Volatility
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More about Beta
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More about CAGR
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More about Information Ratio
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More about Max Drawdown
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More about Sharpe Ratio
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More about Treynor Ratio
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

schema-2

Government lobbying spending instances

  • $45,000 Jan 22, 2024 Issue: Health Issues Medical/Disease Research/Clinical Labs
  • $30,000 Oct 16, 2023 Issue: Health Issues Medical/Disease Research/Clinical Labs
  • $10,000 Jul 20, 2018 Issue: Medical/Disease Research/Clinical Labs
  • $10,000 Apr 20, 2018 Issue: Medical/Disease Research/Clinical Labs
  • $10,000 Jan 18, 2018 Issue: Medical/Disease Research/Clinical Labs
  • $10,000 Oct 20, 2017 Issue: Medical/Disease Research/Clinical Labs

Former government officials who have lobbied for AGEN

Quiver Logo

No former government officials on record as having lobbied for AGEN

Revolving Door Dashboard

AGEN Estimated quarterly lobbying spending

AGEN Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
AGEN Income Statement
AGEN Balance Sheet
AGEN Cash Flow
U.S. Patents

New AGEN patent grants

  • Patent Title: Anti-tigit antibodies and methods of use thereof May. 19, 2026
  • Patent Title: Anti-cd137 antibodies and methods of use thereof Dec. 09, 2025
  • Patent Title: Anti-ctla-4 antibodies and methods of use thereof Dec. 09, 2025
  • Patent Title: Polynucleotide encoding anti-tigit and anti-cd96 antibodies Nov. 25, 2025
  • Patent Title: Anti-ilt4 antibodies and antigen-binding fragments Jul. 01, 2025
  • Patent Title: Anti-ctla-4 antibodies and methods of use thereof Mar. 11, 2025
  • Patent Title: Anti-lag-3 antibodies and methods of use thereof Jan. 07, 2025
  • Patent Title: Anti-tim-3 antibodies and methods of use thereof Jun. 18, 2024
  • Patent Title: Antibodies and methods of use thereof May. 28, 2024
  • Patent Title: Anti-lag-3 antibodies and methods of use thereof May. 28, 2024
  • Patent Title: Anti-gitr antibodies and methods of use thereof Feb. 13, 2024
  • Patent Title: Anti-tim-3 antibodies and methods of use thereof Dec. 12, 2023
  • Patent Title: Anti-tigit and anti-cd96 antibodies Aug. 08, 2023
  • Patent Title: Anti-cd73 antibodies and methods of use thereof Jul. 04, 2023
  • Patent Title: Antibodies that specifically bind human cd96 Jun. 20, 2023
  • Patent Title: Anti-ctla-4 antibodies and methods of use thereof May. 02, 2023
  • Patent Title: Methods of administering anti-ox40 antibodies Oct. 18, 2022
  • Patent Title: Antibodies and methods of use thereof Sep. 20, 2022
  • Patent Title: Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies Aug. 16, 2022
  • Patent Title: Anti-gitr antibodies and methods of use thereof Aug. 02, 2022
  • Patent Title: Anti-ox40 antibodies and anti-gitr antibodies Jun. 14, 2022
  • Patent Title: Anti-pd-1 antibodies and methods of use thereof May. 31, 2022
  • Patent Title: Vectors comprising nucleic acids encoding anti-ox40 antibodies May. 17, 2022
  • Patent Title: Anti-ctla-4 antibodies and methods of use thereof Mar. 08, 2022
  • Patent Title: Anti-cd137 antibodies and methods of use thereof Feb. 08, 2022
  • Patent Title: Anti-ox40 antibodies Oct. 05, 2021
  • Patent Title: Anti-cd137 antibodies and methods of use thereof Aug. 24, 2021
  • Patent Title: Heat shock protein-binding peptide compositions and methods of use thereof Jul. 20, 2021
  • Patent Title: Anti-tigit antibodies and methods of use thereof Jun. 01, 2021
  • Patent Title: Anti-ctla-4 antibodies and methods of use thereof May. 25, 2021
  • Patent Title: Anti-ctla-4 antibodies and methods of use thereof Feb. 09, 2021
  • Patent Title: Anti-tim-3 antibodies and methods of use thereof Feb. 09, 2021
  • Patent Title: Anti-lag-3 antibodies and methods of use thereof Jan. 05, 2021
  • Patent Title: Anti-lag-3 antibodies and methods of use thereof Nov. 24, 2020
  • Patent Title: Antibodies and methods of use thereof Nov. 17, 2020
  • Patent Title: Anti-gitr antibodies and methods of use thereof Nov. 10, 2020
  • Patent Title: Anti-gitr antibodies and methods of use thereof Oct. 13, 2020
  • Patent Title: Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies May. 05, 2020
  • Patent Title: Anti-tim-3 antibodies and methods of use thereof May. 05, 2020
  • Patent Title: Anti-gitr antibodies and methods of use thereof Mar. 03, 2020
  • Patent Title: Vaccines for treatment and prevention of cancer Feb. 25, 2020
  • Patent Title: Identification of antigen- or ligand-specific binding proteins Dec. 10, 2019
  • Patent Title: Anti-ctla-4 antibodies and methods of use thereof Nov. 19, 2019
  • Patent Title: Anti-pd-1 antibodies and methods of use thereof Oct. 22, 2019
  • Patent Title: Anti-pd-1 antibodies and methods of use thereof Jun. 18, 2019
  • Patent Title: Anti-gitr antibodies and methods of use thereof May. 07, 2019
  • Patent Title: Anti-ox40 antibodies Apr. 16, 2019
  • Patent Title: Cell surface display, screening and production of proteins of interest May. 09, 2017
  • Patent Title: Identification of antigen or ligand-specific binding proteins Mar. 14, 2017
  • Patent Title: Vaccine for treatment and prevention of herpes simplex virus infection Sep. 24, 2013
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded to AGEN from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
AGEN News

Recent insights relating to AGEN

CNBC Recommendations

Recent picks made for AGEN stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in AGEN

AGEN Analyst Ratings

AGEN Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
AGEN Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $AGEN stock a Buy, Sell, or Hold?

  • What is the price target for $AGEN stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

AGEN Top Shareholders
Shareholder
Shares Held
AGEN Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $AGEN stock?

  • Who owns the most shares of $AGEN stock?

  • What funds own $AGEN stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

AGEN Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view AGEN Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About AGEN

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

  • Address Lexington, MA
  • Market Cap 379.4 million
  • Employees 81
  • Industrial Classification Biological Products, (No Diagnostic Substances)

Agenus Inc. (AGEN) Historical Stock Prices

Agenus Inc. (AGEN) closed at $8.40 on September 23, 2026. Over the past year its adjusted close ranged from $2.77 to $8.70. Daily prices go back to January 2, 2014, 3,200 trading days in all.

  • 1 month+9.52%
  • 3 months+187.67%
  • Year to date+167.52%
  • 1 year+89.19%
  • 3 years-64.41%
  • 5 years-92.88%
  • Max-84.89%
See every congressional and insider trade on the AGEN price chart

Quiver Premium charts AGEN's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.

Upgrade to Premium

Last 12 months, newest first

Access Raw Data Daily prices since 2014 for every ticker, through the Quiver API
DateOpenHighLowCloseAdj. CloseVolume
Sep 23, 2026 8.70 8.70 8.39 8.40 8.40 610,167
Sep 22, 2026 8.26 8.82 8.16 8.70 8.70 994,136
Sep 21, 2026 7.80 8.60 7.60 8.33 8.33 1,299,720
Sep 18, 2026 7.48 7.88 7.33 7.85 7.85 2,084,681
Sep 17, 2026 7.31 7.40 7.08 7.22 7.22 765,417
Sep 16, 2026 7.25 7.33 7.05 7.21 7.21 687,079
Sep 15, 2026 7.05 7.19 6.81 7.16 7.16 779,518
Sep 14, 2026 7.03 7.18 6.82 7.13 7.13 752,308
Sep 11, 2026 6.93 7.02 6.70 6.94 6.94 790,464
Sep 10, 2026 6.76 7.04 6.66 6.89 6.89 893,555
Sep 9, 2026 7.59 7.61 6.78 6.86 6.86 1,445,780
Sep 8, 2026 8.14 8.18 7.42 7.43 7.43 1,207,777
Sep 4, 2026 8.14 8.38 7.99 8.24 8.24 986,848
Sep 3, 2026 8.12 8.31 7.98 8.24 8.24 738,723
Sep 2, 2026 8.07 8.28 7.68 8.09 8.09 663,995
Sep 1, 2026 7.56 8.00 7.54 7.99 7.99 676,564
Aug 31, 2026 7.68 7.76 7.50 7.61 7.61 721,032
Aug 28, 2026 7.98 8.07 7.61 7.66 7.66 741,161
Aug 27, 2026 8.28 8.52 7.78 7.81 7.81 783,673
Aug 26, 2026 8.30 8.40 8.03 8.25 8.25 779,942
Aug 25, 2026 7.80 8.50 7.80 8.36 8.36 1,181,833
Aug 24, 2026 8.07 8.07 7.60 7.67 7.67 775,158
Aug 21, 2026 7.58 8.35 7.58 8.09 8.09 1,517,511
Aug 20, 2026 8.22 8.25 7.31 7.49 7.49 1,575,849
Aug 19, 2026 7.66 8.73 7.62 8.26 8.26 2,290,360
Aug 18, 2026 7.13 7.64 7.08 7.53 7.53 967,558
Aug 17, 2026 7.30 7.30 6.96 7.15 7.15 831,412
Aug 14, 2026 6.93 7.46 6.83 7.32 7.32 1,251,966
Aug 13, 2026 6.85 7.03 6.71 7.00 7.00 624,951
Aug 12, 2026 6.91 7.20 6.83 6.90 6.90 1,154,187
Aug 11, 2026 6.84 6.89 6.42 6.83 6.83 1,373,565
Aug 10, 2026 6.83 7.09 6.36 7.00 7.00 1,923,046
Aug 7, 2026 7.52 7.55 6.92 6.96 6.96 1,190,970
Aug 6, 2026 7.67 8.85 7.32 7.49 7.49 2,455,450
Aug 5, 2026 8.35 8.52 7.69 7.78 7.78 1,457,472
Aug 4, 2026 7.85 8.38 7.75 8.30 8.30 2,017,318
Aug 3, 2026 7.65 8.09 7.50 7.82 7.82 1,654,258
Jul 31, 2026 7.79 7.98 7.32 7.50 7.50 1,573,848
Jul 30, 2026 6.77 7.99 6.51 7.91 7.91 3,002,899
Jul 29, 2026 6.61 6.95 6.48 6.63 6.63 1,857,226
Jul 28, 2026 6.06 6.64 5.88 6.60 6.60 2,785,167
Jul 27, 2026 5.99 6.20 5.87 6.13 6.13 1,234,481
Jul 24, 2026 6.20 6.23 5.81 5.98 5.98 1,249,283
Jul 23, 2026 5.53 6.22 5.46 6.19 6.19 2,333,435
Jul 22, 2026 5.57 5.89 5.50 5.53 5.53 1,698,697
Jul 21, 2026 5.00 5.90 4.99 5.58 5.58 2,602,570
Jul 20, 2026 5.06 5.46 4.94 4.97 4.97 1,969,278
Jul 17, 2026 4.91 5.14 4.78 5.01 5.01 1,754,750
Jul 16, 2026 5.00 5.28 4.67 5.00 5.00 2,696,460
Jul 15, 2026 5.19 5.19 4.66 5.01 5.01 4,491,064
Jul 14, 2026 6.12 6.28 4.99 5.08 5.08 11,110,968
Jul 13, 2026 5.42 8.70 4.91 6.12 6.12 174,277,926
Jul 10, 2026 3.24 3.38 3.10 3.35 3.35 833,400
Jul 9, 2026 3.25 3.35 3.19 3.24 3.24 654,170
Jul 8, 2026 3.47 3.63 3.25 3.25 3.25 797,540
Jul 7, 2026 3.36 3.58 3.25 3.50 3.50 1,164,347
Jul 6, 2026 3.50 3.55 3.41 3.41 3.41 548,115
Jul 2, 2026 3.40 3.52 3.37 3.49 3.49 680,579
Jul 1, 2026 3.06 3.43 3.06 3.41 3.41 660,413
Jun 30, 2026 3.18 3.20 3.02 3.06 3.06 644,548
Jun 29, 2026 3.03 3.23 2.96 3.15 3.15 947,439
Jun 26, 2026 2.88 3.10 2.87 3.03 3.03 5,006,329
Jun 25, 2026 2.97 3.04 2.85 2.88 2.88 594,632
Jun 24, 2026 3.07 3.13 2.90 2.92 2.92 625,201
Jun 23, 2026 2.99 3.18 2.99 3.07 3.07 438,569
Jun 22, 2026 2.99 3.10 2.98 3.04 3.04 476,300
Jun 18, 2026 3.00 3.10 2.91 3.00 3.00 868,396
Jun 17, 2026 3.02 3.05 2.86 2.96 2.96 724,047
Jun 16, 2026 3.26 3.39 2.97 2.98 2.98 836,459
Jun 15, 2026 3.36 3.44 3.24 3.25 3.25 455,024
Jun 12, 2026 3.40 3.45 3.29 3.30 3.30 505,335
Jun 11, 2026 3.09 3.42 3.04 3.39 3.39 1,214,733
Jun 10, 2026 3.11 3.17 3.06 3.07 3.07 759,000
Jun 9, 2026 3.20 3.31 3.10 3.11 3.11 499,225
Jun 8, 2026 3.30 3.32 3.12 3.14 3.14 367,663
Jun 5, 2026 3.38 3.38 3.19 3.23 3.23 434,606
Jun 4, 2026 3.23 3.48 3.23 3.40 3.40 514,785
Jun 3, 2026 3.36 3.42 3.21 3.22 3.22 467,032
Jun 2, 2026 3.44 3.52 3.36 3.38 3.38 413,049
Jun 1, 2026 3.52 3.53 3.33 3.48 3.48 864,631
May 29, 2026 3.41 3.50 3.30 3.50 3.50 617,262
May 28, 2026 3.41 3.44 3.29 3.40 3.40 670,613
May 27, 2026 3.36 3.53 3.34 3.41 3.41 466,634
May 26, 2026 3.14 3.42 3.14 3.32 3.32 703,044
May 22, 2026 3.30 3.36 3.05 3.11 3.11 901,410
May 21, 2026 3.12 3.21 3.08 3.16 3.16 435,655
May 20, 2026 3.12 3.25 3.12 3.15 3.15 471,460
May 19, 2026 3.20 3.21 3.02 3.09 3.09 679,191
May 18, 2026 3.56 3.56 3.07 3.16 3.16 1,042,442
May 15, 2026 3.52 3.60 3.42 3.58 3.58 511,890
May 14, 2026 3.47 3.62 3.37 3.58 3.58 434,481
May 13, 2026 3.41 3.58 3.39 3.47 3.47 575,794
May 12, 2026 3.25 3.45 3.21 3.44 3.44 799,546
May 11, 2026 3.61 3.67 3.20 3.26 3.26 2,016,183
May 8, 2026 3.77 3.92 3.71 3.82 3.82 621,821
May 7, 2026 3.90 3.90 3.66 3.75 3.75 1,056,973
May 6, 2026 4.20 4.24 3.85 3.89 3.89 1,548,158
May 5, 2026 4.06 4.27 4.05 4.17 4.17 877,075
May 4, 2026 3.84 4.04 3.79 4.02 4.02 740,761
May 1, 2026 3.87 3.88 3.78 3.84 3.84 518,853
Apr 30, 2026 3.89 4.00 3.77 3.91 3.91 582,198
Apr 29, 2026 3.87 3.87 3.64 3.84 3.84 572,549
Apr 28, 2026 4.06 4.20 3.87 3.89 3.89 672,098
Apr 27, 2026 3.97 4.57 3.93 4.09 4.09 1,775,127
Apr 24, 2026 3.76 3.97 3.68 3.90 3.90 770,404
Apr 23, 2026 3.94 3.96 3.75 3.76 3.76 840,267
Apr 22, 2026 3.99 4.11 3.88 3.94 3.94 770,656
Apr 21, 2026 4.44 4.44 3.91 3.91 3.91 1,358,470
Apr 20, 2026 4.55 4.70 4.36 4.42 4.42 1,305,058
Apr 17, 2026 4.70 4.80 4.52 4.79 4.79 827,402
Apr 16, 2026 4.70 4.80 4.57 4.64 4.64 795,227
Apr 15, 2026 4.77 5.08 4.56 4.83 4.83 1,475,826
Apr 14, 2026 4.27 4.79 4.25 4.72 4.72 2,670,799
Apr 13, 2026 3.91 4.30 3.90 4.15 4.15 1,297,024
Apr 10, 2026 4.59 4.67 3.85 3.96 3.96 2,104,665
Apr 9, 2026 4.19 4.50 4.09 4.45 4.45 1,154,850
Apr 8, 2026 4.19 4.27 4.04 4.20 4.20 1,301,467
Apr 7, 2026 3.77 4.14 3.58 4.06 4.06 1,844,198
Apr 6, 2026 3.37 4.00 3.35 3.77 3.77 1,855,786
Apr 2, 2026 3.33 3.41 3.24 3.33 3.33 480,752
Apr 1, 2026 3.40 3.50 3.38 3.40 3.40 324,980
Mar 31, 2026 3.25 3.44 3.25 3.34 3.34 394,451
Mar 30, 2026 3.39 3.39 3.23 3.24 3.24 257,491
Mar 27, 2026 3.44 3.47 3.34 3.39 3.39 321,688
Mar 26, 2026 3.50 3.52 3.41 3.44 3.44 252,662
Mar 25, 2026 3.60 3.68 3.54 3.56 3.56 255,486
Mar 24, 2026 3.68 3.70 3.50 3.56 3.56 379,215
Mar 23, 2026 3.78 3.86 3.62 3.69 3.69 303,759
Mar 20, 2026 3.83 3.83 3.65 3.71 3.71 382,624
Mar 19, 2026 3.70 3.87 3.62 3.81 3.81 455,107
Mar 18, 2026 3.98 4.08 3.65 3.76 3.76 1,010,576
Mar 17, 2026 3.34 4.10 3.30 3.99 3.99 1,688,090
Mar 16, 2026 3.12 3.41 2.92 3.29 3.29 905,728
Mar 13, 2026 3.02 3.18 3.02 3.10 3.10 314,436
Mar 12, 2026 3.26 3.31 2.97 2.98 2.98 610,576
Mar 11, 2026 3.39 3.39 3.21 3.31 3.31 290,608
Mar 10, 2026 3.21 3.55 3.21 3.37 3.37 844,601
Mar 9, 2026 2.95 3.17 2.90 3.15 3.15 453,996
Mar 6, 2026 2.92 3.04 2.92 2.96 2.96 413,948
Mar 5, 2026 3.14 3.19 2.91 2.92 2.92 1,030,505
Mar 4, 2026 3.21 3.27 3.10 3.20 3.20 247,008
Mar 3, 2026 3.26 3.28 3.14 3.18 3.18 392,980
Mar 2, 2026 3.20 3.36 3.15 3.34 3.34 298,897
Feb 27, 2026 3.26 3.33 3.23 3.33 3.33 224,896
Feb 26, 2026 3.22 3.38 3.14 3.36 3.36 204,298
Feb 25, 2026 3.22 3.29 3.15 3.23 3.23 370,134
Feb 24, 2026 3.06 3.35 3.02 3.22 3.22 407,990
Feb 23, 2026 3.03 3.08 3.00 3.07 3.07 175,485
Feb 20, 2026 3.19 3.25 3.03 3.06 3.06 400,416
Feb 19, 2026 3.06 3.21 3.02 3.21 3.21 365,213
Feb 18, 2026 3.03 3.13 2.94 3.08 3.08 390,886
Feb 17, 2026 2.92 3.07 2.90 3.05 3.05 432,822
Feb 13, 2026 2.83 3.00 2.83 2.92 2.92 280,692
Feb 12, 2026 2.99 2.99 2.75 2.85 2.85 337,947
Feb 11, 2026 3.06 3.08 2.88 2.98 2.98 525,138
Feb 10, 2026 3.03 3.15 2.96 3.07 3.07 658,508
Feb 9, 2026 2.91 3.01 2.84 2.98 2.98 273,330
Feb 6, 2026 2.78 3.01 2.78 2.94 2.94 490,206
Feb 5, 2026 2.85 2.88 2.71 2.77 2.77 490,733
Feb 4, 2026 2.91 2.96 2.77 2.89 2.89 458,321
Feb 3, 2026 2.90 2.93 2.81 2.90 2.90 486,270
Feb 2, 2026 2.85 2.97 2.80 2.86 2.86 502,843
Jan 30, 2026 2.94 2.95 2.81 2.84 2.84 533,065
Jan 29, 2026 3.16 3.16 2.96 2.99 2.99 805,517
Jan 28, 2026 3.20 3.21 3.08 3.11 3.11 373,306
Jan 27, 2026 3.03 3.20 3.00 3.19 3.19 510,147
Jan 26, 2026 3.23 3.23 2.95 3.02 3.02 1,189,717
Jan 23, 2026 3.40 3.40 3.22 3.24 3.24 476,294
Jan 22, 2026 3.41 3.54 3.34 3.38 3.38 460,692
Jan 21, 2026 3.42 3.55 3.26 3.40 3.40 889,107
Jan 20, 2026 3.30 3.39 3.12 3.37 3.37 851,306
Jan 16, 2026 3.67 3.76 3.31 3.34 3.34 1,738,937
Jan 15, 2026 4.69 4.83 3.61 3.68 3.68 3,180,032
Jan 14, 2026 4.59 4.87 4.57 4.68 4.68 1,242,238
Jan 13, 2026 4.27 4.69 4.15 4.61 4.61 1,452,855
Jan 12, 2026 4.00 4.31 3.83 4.25 4.25 941,563
Jan 9, 2026 3.80 4.00 3.80 3.91 3.91 685,819
Jan 8, 2026 3.74 3.85 3.60 3.75 3.75 666,407
Jan 7, 2026 3.47 3.85 3.46 3.70 3.70 955,319
Jan 6, 2026 3.25 3.57 3.25 3.47 3.47 907,282
Jan 5, 2026 3.26 3.34 3.17 3.22 3.22 278,759
Jan 2, 2026 3.18 3.23 3.09 3.23 3.23 356,885
Dec 31, 2025 3.10 3.20 3.06 3.14 3.14 402,663
Dec 30, 2025 3.17 3.23 3.01 3.12 3.12 809,738
Dec 29, 2025 3.27 3.30 3.08 3.19 3.19 667,650
Dec 26, 2025 3.33 3.36 3.19 3.31 3.31 733,445
Dec 24, 2025 3.27 3.41 3.27 3.35 3.35 394,109
Dec 23, 2025 3.51 3.52 3.25 3.31 3.31 630,079
Dec 22, 2025 3.41 3.56 3.38 3.51 3.51 512,434
Dec 19, 2025 3.50 4.00 3.01 3.44 3.44 2,838,845
Dec 18, 2025 3.60 3.72 3.51 3.51 3.51 338,931
Dec 17, 2025 3.73 3.79 3.58 3.59 3.59 236,098
Dec 16, 2025 3.69 3.77 3.63 3.72 3.72 381,130
Dec 15, 2025 3.82 3.85 3.69 3.71 3.71 604,361
Dec 12, 2025 4.07 4.07 3.79 3.79 3.79 836,731
Dec 11, 2025 4.09 4.12 4.00 4.08 4.08 246,490
Dec 10, 2025 3.91 4.10 3.82 4.09 4.09 494,094
Dec 9, 2025 4.02 4.04 3.89 3.92 3.92 478,956
Dec 8, 2025 3.97 4.12 3.97 4.03 4.03 490,739
Dec 5, 2025 4.06 4.09 3.92 3.93 3.93 872,807
Dec 4, 2025 4.17 4.17 3.97 4.06 4.06 516,587
Dec 3, 2025 4.17 4.25 4.13 4.17 4.17 390,074
Dec 2, 2025 4.34 4.34 4.05 4.17 4.17 461,899
Dec 1, 2025 4.45 4.50 4.25 4.32 4.32 599,372
Nov 28, 2025 4.60 4.64 4.51 4.56 4.56 186,171
Nov 26, 2025 4.40 4.58 4.34 4.55 4.55 549,373
Nov 25, 2025 4.29 4.48 4.29 4.38 4.38 387,012
Nov 24, 2025 4.24 4.47 4.23 4.29 4.29 488,373
Nov 21, 2025 4.27 4.30 4.11 4.22 4.22 374,401
Nov 20, 2025 4.28 4.49 4.19 4.29 4.29 373,085
Nov 19, 2025 4.22 4.30 4.12 4.20 4.20 267,946
Nov 18, 2025 4.32 4.38 4.12 4.23 4.23 405,058
Nov 17, 2025 4.36 4.59 4.28 4.32 4.32 490,310
Nov 14, 2025 4.21 4.45 4.17 4.34 4.34 366,427
Nov 13, 2025 4.39 4.42 4.25 4.33 4.33 434,993
Nov 12, 2025 4.25 4.67 4.22 4.43 4.43 722,742
Nov 11, 2025 4.18 4.40 4.18 4.27 4.27 658,546
Nov 10, 2025 3.98 4.69 3.97 4.21 4.21 1,237,498
Nov 7, 2025 3.84 3.98 3.70 3.98 3.98 437,344
Nov 6, 2025 3.70 3.89 3.70 3.84 3.84 419,825
Nov 5, 2025 3.72 3.84 3.63 3.69 3.69 333,232
Nov 4, 2025 3.87 3.94 3.71 3.73 3.73 505,568
Nov 3, 2025 3.97 4.00 3.85 3.97 3.97 552,099
Oct 31, 2025 3.99 4.11 3.90 3.97 3.97 469,325
Oct 30, 2025 3.85 3.92 3.77 3.81 3.81 261,010
Oct 29, 2025 4.03 4.03 3.83 3.85 3.85 669,601
Oct 28, 2025 4.14 4.15 3.97 4.04 4.04 191,079
Oct 27, 2025 4.09 4.22 4.09 4.15 4.15 196,318
Oct 24, 2025 4.24 4.24 3.95 4.14 4.14 401,325
Oct 23, 2025 4.05 4.24 4.04 4.18 4.18 540,029
Oct 22, 2025 4.25 4.26 4.00 4.05 4.05 563,435
Oct 21, 2025 4.42 4.46 4.13 4.29 4.29 480,092
Oct 20, 2025 3.97 4.60 3.95 4.42 4.42 928,072
Oct 17, 2025 4.00 4.10 3.85 3.88 3.88 552,074
Oct 16, 2025 4.05 4.18 3.95 3.99 3.99 523,305
Oct 15, 2025 3.99 4.01 3.84 3.98 3.98 391,805
Oct 14, 2025 3.99 3.99 3.83 3.97 3.97 356,121
Oct 13, 2025 3.98 4.07 3.92 4.05 4.05 384,260
Oct 10, 2025 4.26 4.26 3.95 3.97 3.97 327,101
Oct 9, 2025 4.23 4.40 4.22 4.25 4.25 449,543
Oct 8, 2025 4.15 4.23 4.12 4.17 4.17 351,667
Oct 7, 2025 4.20 4.38 4.12 4.25 4.25 592,776
Oct 6, 2025 4.14 4.21 4.07 4.15 4.15 406,228
Oct 3, 2025 4.00 4.34 3.92 4.14 4.14 826,783
Oct 2, 2025 3.91 3.96 3.87 3.94 3.94 289,040
Oct 1, 2025 3.85 3.99 3.82 3.90 3.90 296,345
Sep 30, 2025 3.94 3.97 3.76 3.85 3.85 439,623
Sep 29, 2025 4.00 4.05 3.92 3.98 3.98 336,974
Sep 26, 2025 3.90 3.98 3.78 3.95 3.95 494,715
Sep 25, 2025 4.23 4.23 3.87 3.90 3.90 853,318
Sep 24, 2025 4.49 4.53 4.25 4.27 4.27 394,564
Sep 23, 2025 4.51 4.67 4.42 4.44 4.44 424,017

Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.

Need daily prices for every ticker, in code?

The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.

Explore the Quiver API
Agenus Inc. Executive Compensation

We estimate that -- received a compensation of -- in --, making them the highest paid executive at AGEN, per a recent SEC DEF 14A filing. We estimate that the median employee at AGENUS INC is paid $114,901.



Name
Role
Salary
Bonus
Stock/Option Awards
Total Compensation